Dr. Reddy’s Laboratories Limited

Dr. Reddy's Laboratories Limited was established in 1984 by Dr. K. Anji Reddy, a visionary entrepreneur and scientist with a passion for making quality medicines accessible and affordable to everyone. Over the years, the company has evolved into a global enterprise, with research and development facilities, manufacturing plants, and a commercial presence worldwide. With its innovative and generic drugs, the company serves over half a billion patients in more than 40 countries. As of 2022, Dr. Reddy's Laboratories' revenue was roughly INR 20,000 crores.

The company's diverse product portfolio includes a range of therapy areas, such as gastroenterology, oncology, pain management, cardiovascular, dermatology, urology, nephrology, rheumatology, and diabetes. Dr. Reddy's Laboratories has also developed several biosimilars and complex generics that offer improved treatment options for patients. Some of the company’s flagship brands include Omez (omeprazole), Nise (nimesulide), Stamlo (amlodipine), Razo (rabeprazole), Ciprolet (ciprofloxacin), and Mintop (minoxidil).

Dr. Reddy’s Laboratories Limited is not only a maker of molecules but also a provider of medicines that go beyond the pill. The company has launched several initiatives under its Purple Health platform to address the unmet needs of patients and caregivers. These include disease awareness and convenient diagnosis programs, access to medicines schemes, better therapy experience solutions, and adherence to therapy support.

Foundation: 1984
Headquarters: Hyderabad, Telangana

Website: https://www.drreddys.com/